Evaluating brain stimulation for methamphetamine use disorders
The Exploration of Novel Cross-frequency Protocol of Transcranial Alternating Current Stimulation in the Treatment of Methamphetamine Use Disorder: A Randomized Sham-controlled Study
This study is testing if a special type of brain stimulation can help people with methamphetamine use disorders by reducing cravings and improving brain function.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 32 (estimated) |
| Ages | 18 Years to 59 Years |
| Sex | All |
| Sponsor | Shanghai Mental Health Center Academic / other |
| Locations | 1 site (Wuhan) |
| Trial ID | NCT06145698 on ClinicalTrials.gov |
What this trial studies
This research aims to assess the effectiveness of theta-gamma cross-frequency transcranial alternating current stimulation (tACS) in patients with methamphetamine use disorders. The study will involve multiple sessions of stimulation, comparing the effects of active tACS against a sham treatment. Participants will undergo electroencephalography (EEG) assessments before and after each session to measure changes in brain activity related to cognitive functions and craving responses. The goal is to provide causal evidence linking brain oscillatory activity to addiction-related behaviors.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with methamphetamine use disorders who have not used the drug for at least three months.
Not a fit: Patients with cognitive impairments due to other medical conditions or those currently using other substances may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve cognitive function and reduce cravings in patients with methamphetamine use disorders.
How similar studies have performed: While the approach is innovative, previous studies have shown promising results with brain stimulation techniques in addiction treatment, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) for methamphetamine (MA) use disorders 2. Normal vision and hearing 3. Dextromanual 4. Use MA not less than 1 year, and the last of MA use no less than 3 months Exclusion Criteria: 1. Have a disease that affects cognitive function such as a history of head injury, cerebrovascular disease, epilepsy, etc 2. Have cognitive-promoting drugs in the last 6 months 3. Other substance abuse or dependence in recent five years (except nicotine) 4. Meet the DSM-5 criteria for other mental disorders 5. Physical disease
Where this trial is running
Wuhan
- Wuhan Compulsory Rehabilitation Center — Wuhan, China (Recruiting)
Study contacts
- Study coordinator: Min Zhao, PhD
- Email: 18017311005@163.com
- Phone: 021-54252689
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.